Quick Search


 

Result Summaries: maraviroc

ViiV
Study ID
   Phase    Title Summary (Download)
115647 phase 4 A multicentre observational study to evaluate the effectiveness, safety and treatment costs of maraviroc used with optimized background therapy in treatment-experienced HIV infected patients in routine clinical practice in Portugal (0 citation(s)) Click here to download result summary.
116268 n\a Comparison of Maraviroc to Efavirenz, Atazanavir, Darunavir, Lopinavir/Ritonavir, and Raltegravir for Treatment-Naïve Persons with CCR5-Positive HIV-1 in Canada (0 citation(s)) Click here to download result summary.
116483 n\a Protocol to evaluate the public health value of maraviroc using the French hospital databaseon HIV infection (FHDH) (0 citation(s)) Click here to download result summary.
A4001031 Phase 2 An Open-label, Multicenter, Multiple-dose Pharmacokinetic, Safety And Efficacy Trial Of Maraviroc In Combination With Optimized Background Therapy For The Treatment Of Antiretroviral-experienced Ccr5-tropic Hiv-1 Infected Children 2 - <18 Years Of Age (1 citation(s)) Click here to download result summary.
A4001095 Phase 3 A MULTICENTER, RANDOMIZED, DOUBLE‑BLIND, COMPARATIVE TRIAL OF MARAVIROC + DARUNAVIR/RITONAVIR VERSUS EMTRICITABINE/TENOFOVIR + DARUNAVIR/RITONAVIR FOR THE TREATMENT OF ANTIRETROVIRAL‑NAIVE HIV‑INFECTED PATIENTS WITH CCR5‑TROPIC HIV‑1 (1 citation(s)) Click here to download result summary.
A4001098 Phase 4 A MULTICENTER, RANDOMIZED, BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY OF MARAVIROC IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS IN HIV-1-INFECTED SUBJECTS CO-INFECTED WITH HEPATITIS C AND/OR HEPATITIS B VIRUS (1 citation(s)) Click here to download result summary.
A4001101 Phase 4 A Multicenter, Open-label Study of Maraviroc, Zidovudine and Lamivudine Twice Daily for the Treatment of Antiretroviral Naïve HIV-Infected Patients with R5 HIV-1 in Russia (1 citation(s)) Click here to download result summary.
A4001105 Phase 2 SELECTED CLINICAL EVENTS AMONG HIV-INFECTED AND HIV UNINFECTED PERSONS ENROLLED IN KAISER PERMANENTE (1 citation(s)) Click here to download result summary.
A4001110 Phase 1 A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/cobicistat In African-american And Caucasian Healthy Volunteers (1 citation(s)) Click here to download result summary.